Related Experiment Video

Updated: Aug 25, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
08:23

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

Nitric oxide: potential role for reducing gastro-enteropathy

Matthew Walley1, Christoph Hotz-Behofsits, Robert Simpson

  • 1Department of Medicine, Guys, Kings and St Thomas' School of Medicine, Bessemer Road, London SE5 9PJ, UK. matthew.walley@kcl.ac.uk

Inflammopharmacology
|March 24, 2004
PubMed

Insights

Non-steroidal anti-inflammatory drug (NSAID)-induced gastroenteropathy involves increased intestinal permeability and ulcers. Nitric oxide-releasing NSAIDs (NO-NSAIDs) may counteract these damaging effects by releasing nitric oxide (NO).

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Drug Development

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) can cause significant gastrointestinal damage, including increased intestinal permeability, inflammation, and ulcer formation.
  • These effects are attributed to topical injury and micro-vascular changes resulting from cyclooxygenase-1 (COX-1) inhibition and prostaglandin deficiency.

Purpose of the Study:

  • To examine the mechanisms underlying NSAID-induced gastrointestinal damage.
  • To review strategies developed to mitigate NSAID toxicity.
  • To explore the potential of nitric oxide (NO) and NO-releasing NSAIDs (NO-NSAIDs) in preventing NSAID-induced gastroenteropathy.

Main Methods:

  • Review of proposed pathogenic mechanisms of NSAID-induced gastroenteropathy.
  • Analysis of various strategies employed to reduce NSAID toxicity.
  • Examination of the physiological roles of nitric oxide (NO) in the gastrointestinal tract.

Main Results:

  • NSAID-induced gastroenteropathy involves topical effects and micro-vascular changes.
  • Nitric oxide (NO) plays a physiological role in the gut.
  • Nitric oxide-releasing NSAIDs (NO-NSAIDs) are a novel strategy to counteract NSAID-induced mucosal damage.

Conclusions:

  • NSAID-induced gastrointestinal damage is multifactorial.
  • Nitric oxide (NO) may serve as a protective agent against NSAID toxicity.
  • NO-NSAIDs represent a promising therapeutic approach to limit NSAID-related gastrointestinal side effects.

More Related Videos

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements07:19

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Published on: July 29, 2021

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...